Capricor Therapeutics (CAPR) Share-based Compensation (2010 - 2026)

Capricor Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 2198.62% year-over-year to $5.9 million in Q1 2026; TTM through Mar 2026 was $19.0 million, a 1161.58% increase from a year earlier, with the FY2025 full-year figure at $13.4 million, down 34.4% from the prior year.
• Share-based Compensation improved to $5.9 million in Q1 2026 per CAPR's latest filing, from $4.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.6 million in Q3 2024 and bottomed at -$7.5 million in Q4 2024.
• The 5-year median for Share-based Compensation is $1.8 million (2023), against an average of $2.9 million.
• Across the five-year window, Share-based Compensation sank 501.22% in 2024 and soared 2198.62% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $1.1 million in 2022, then jumped by 62.14% to $1.9 million in 2023, then sank by 501.22% to -$7.5 million in 2024, then jumped by 156.94% to $4.3 million in 2025, then jumped by 39.15% to $5.9 million in 2026.
• Per Business Quant, the three latest CAPR Share-based Compensation figures stand at $5.9 million (Q1 2026), $4.3 million (Q3 2025), and $8.9 million (Q2 2025).